ArticleLeukemia2021
Risk of infections in patients with myeloproliferative neoplasms-a population-based cohort study of 8363 patients.
Article in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Guideline
- Clinical and prognostic significance of concomitant autoimmune disease in patients with myelofibrosis.Annals of hematology · 2026Article
- Disseminated Tuberculosis Mimicking Metastatic Cancer During Ruxolitinib Therapy for Polycythemia Vera: A Case Report and Literature Review.The American journal of case reports · 2026Review
- Risk of Transformation to Acute Myeloid Leukaemia and Myelodysplastic Syndromes in Patients With Myeloproliferative Neoplasms Over Attained Age and Time Since Diagnosis: A Nationwide Cohort Study.European journal of haematology · 2026Article
- Loss of life expectancy in patients with myeloproliferative neoplasms in Sweden.Haematologica · 2026Article
- The dual crisis of coronary thrombosis and sepsis in JAK2-mutated essential thrombocytosis: A clinical case report.Medicine · 2026Article
- Long-Term Safety Profile of Ruxolitinib in Chronic Myeloproliferative Neoplasms: A Comprehensive Real-World Analysis.EJHaem · 2025Article
- Patient Characteristics, Healthcare Contacts and Drug Use in Polycythaemia Vera in Denmark.European journal of haematology · 2025Article
- Proinflammatory and prothrombotic conditions in JAK2V617F-positive MPN: a case of Lemierre's syndrome in essential thrombocythemia.Annals of hematology · 2025Article
- Intersecting Pathologies: Polycythemia Vera and Recurrent Infections in an Elderly Patient.Cureus · 2025Article
- Article
- Cost-utility analysis of ropeginterferon alfa-2b to manage low-risk patients with polycythemia vera as compared to phlebotomy only in the Austrian healthcare system.Annals of hematology · 2025Article
- Washed microbiota transplantation stopped recurrent sepsis in a patient with myelofibrosis: a case report.Gut pathogens · 2024Article
- Infections in patients with mantle cell lymphoma.HemaSphere · 2024Article
- Acute invasive fungal sinusitis with orbital tip syndrome in patients on long-term use of ruxolitinib: a case report.Journal of medical case reports · 2024Article
- Disseminated Histoplasmosis in a Patient with Myelofibrosis on Ruxolitinib: A Case Report and Review of the Literature on Ruxolitinib-Associated Invasive Fungal Infections.Journal of fungi (Basel, Switzerland) · 2024Review
- Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives.Frontiers in oncology · 2024Review
- Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape.International journal of molecular sciences · 2023Review
- Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety.Journal of hematology & oncology · 2023Review
- Myelofibrosis.Blood · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Infections are a common complication in patients with many hematologic malignancies, however, whether patients with myeloproliferative neoplasms (MPN) also are at an increased risk of infections is largely unknown. To assess the risk of serious infections, we performed a large population-based matched cohort study in Sweden including 8 363 MPN patients and 32,405 controls using high-quality registers between the years 1992-2013 with follow-up until 2015. The hazard ratio (HR) of any infection was 2.0 (95% confidence interval 1.9-2.0), of bacterial infections 1.9 (1.8-2.0), and of viral infections 2.1 (1.9-2.3). One of the largest risk increases was that of sepsis, HR 2.6 (2.4-2.9). The HR of any infection was highest in primary myelofibrosis 3.7 (3.2-4.1), and significantly elevated in all MPN subtypes; 1.7 (1.6-1.8) in polycythemia vera and 1.7 (1.5-1.8) in essential thrombocythemia. There was no significant difference in risk of infections between untreated patients and patients treated with hydroxyurea or interferon-α during the years 2006-2013. These novel findings of an overall increased risk of infections in MPN patients, irrespective of common cytoreductive treatments, suggest the increased risk of infection is inherent to the MPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.